T001 HHSN2610009 (old 000509388-T008) Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Evaluating Whether a Concurrent Retinoid X Receptor Agonist Can Enhance the Efficacy of HER2-IGFPB2-IGFLR Vaccine in Eliminating Existing Ductal Carcinoma in Situ and Preventing Progression of Invasive Breast Cancer

Grant

Date/time Interval

  • April 1, 2020 - January 14, 2022
  • Total Award Amount

  • 588219.00
  • Direct Costs

  • 567178.00
  • Sponsor Award Id

  • Contributor

  • Gregory Kennedy M.D.   Principal Investigator